Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
RESEARCH TOOLSreports
Holding CLSD?
Track your performance easily
Earnings Data
Report Date
Mar 18, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.1Last Year’s EPS
-$0.08Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -21.44%
|Next Earnings Date:Mar 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic partnerships, and financial stability. The positive results from the ODYSSEY trial and strategic collaborations provide a strong foundation for future developments. However, there are uncertainties related to the Phase III plans and geographic atrophy research timeline.Company Guidance
During the Clearside Biomedical Q3 2024 earnings call, the management provided comprehensive guidance on the company's progress and future plans. They highlighted the positive outcomes from the ODYSSEY Phase IIb clinical trial for CLS-AX in wet AMD, which demonstrated a favorable safety profile, stable best corrected visual acuity, and a significant reduction in treatment frequency by 84% with dosing flexibility between 3 to 6 months. The management anticipates starting two Phase III trials in the second half of 2025, with plans to discuss trial specifics in an end-of-Phase II meeting with the FDA early in 2025. Financially, the company reported cash and cash equivalents of approximately $23.6 million as of September 30, 2024, which is expected to support operations into Q3 2025, including preparations for the Phase III program and geographic atrophy research. Additionally, they discussed the strategic importance of their suprachoroidal platform, emphasizing its potential to address a $20 billion market in geographic atrophy and ongoing collaborations with partners like Arctic Vision and REGENXBIO.Positive ODYSSEY Phase IIb Results
The ODYSSEY trial showed positive results for CLS-AX in treating wet AMD, demonstrating efficacy, safety, and potential for reduced treatment burden. The trial showed a 84% reduction in injection frequency, with most patients not requiring additional treatment for up to 6 months.
Strategic Collaborations and Partnerships
Clearside has strategic collaborations with Arctic Vision, REGENXBIO, and others, expanding the reach and validation of their suprachoroidal platform. Notably, Arctic Vision's collaboration with Santen Pharmaceuticals and REGENXBIO's partnership with AbbVie to advance gene therapy.
Expansion into Geographic Atrophy
Research is underway to explore treatments for geographic atrophy, a market valued at over $20 billion. Two approaches are being evaluated: improving choroidal perfusion and moderating inflammatory cells.
Financial Stability
As of September 30, 2024, Clearside had approximately $23.6 million in cash and cash equivalents, sufficient to fund operations into the third quarter of 2025.
Leadership and Structural Enhancements
Key personnel changes, including Tony Gibney as Chair of the Board and expanded responsibilities for Victor Chong, strengthen Clearside's leadership team.
---
CLSD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLSD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $1.11 | $1.08 | -2.70% |
| Aug 12, 2024 | $1.07 | $1.06 | -0.93% |
| May 09, 2024 | $1.35 | $1.25 | -7.41% |
| Mar 12, 2024 | $1.64 | $1.63 | -0.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Clearside Biomedical (CLSD) report earnings?
Clearside Biomedical (CLSD) is schdueled to report earning on Mar 18, 2025, TBA Not Confirmed.
What is Clearside Biomedical (CLSD) earnings time?
Clearside Biomedical (CLSD) earnings time is at Mar 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLSD EPS forecast?
CLSD EPS forecast for the fiscal quarter 2024 (Q4) is -$0.1.
---